XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Summary of Significant Accounting Policies (Tables)
 6 Months Ended
Jun. 30, 2024
Accounting Policies [Abstract]  
Schedule of the outstanding securities not included in the computation of diluted net loss per common share as their inclusion would be anti-dilutive The following table summarizes outstanding securities not included in the computation of diluted net loss per common share, as their inclusion would be anti-dilutive:
Outstanding at June 30,
20242023
Common stock options1,772,8072,583,540
Restricted stock units508,947222,300
Performance-based restricted stock units235,520—
Preferred stock2,369,7972,369,797
Warrants3,625,24418,403
Schedules of Concentration of Risk, by Risk Factor The following customers accounted for over 10% of total gross product revenue during three months ended June 30, 2024. As the Company launched Rezdiffra in April 2024, there were no sales and no corresponding customer concentrations in prior periods.
Three Months Ended June 30,
20242023
Customer A
39 %— %
Customer B
19 %— %
Customer C
16 %— %
Customer D
14 %— %